Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityAnalysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patientsN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisMinor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureA strategy to model nonmonotonic dose-response curve and estimate IC50Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strainsLoss and recovery of genetic diversity in adapting populations of HIVJoint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data.Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Genotypic testing for human immunodeficiency virus type 1 drug resistance.The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjectsEffect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Resistance and cross-resistance to abacavir.Salvage antiretroviral therapy in HIV infection.In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1Managing failure to antiretroviral drugs in HIV-1-infected patients.Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.Fifteen years later: hard and soft selection sweeps confirm a large population number for HIV in vivo.Identification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex.Recursive partitioning of resistant mutations for longitudinal markers based on a U-type score.Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection.HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcriptionIn vitro resistance profile of the candidate HIV-1 microbicide drug dapivirineImperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in repRelative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
P2860
Q24628212-CD322638-1BED-40DE-BE7F-C047904BB4B3Q24795766-E1FB90CF-ABF1-487B-BAC7-403A22BBB719Q28471689-B423E902-E6B4-4F2D-8FE2-109A3CA35B91Q28478121-D7C67577-1A87-4418-A8FC-B77468A58FFCQ28478779-77C4DFA5-C2E3-4F3B-9281-173C59F8CCAFQ28535044-CFE54FE1-44F4-4583-B8F2-00EEABF38162Q28537991-D2011BBF-298D-40A9-9182-A926D879FC1BQ28539052-57C9094F-6C65-4012-A5EC-E96E9FFA5489Q31109931-2AE34C0D-8EEC-49CA-B2FF-57F3726FF5B3Q33483060-FCC5A51A-0575-4734-B451-2E80F81F6119Q33592278-CFB2F0A7-C9A9-4BF0-B1BD-F7F6D934A61AQ33601530-0BCC5DA2-4BA7-4F29-9DD8-583502699C3DQ33622741-4539B953-46A9-46A0-8920-C397797720DEQ33624190-0E4BCE34-41BA-4B79-B43D-A110B3828040Q33649563-FA2DFD3F-D92F-4C4C-B62C-C7D93271AF73Q33768822-520756D6-F353-4A10-B9CB-B93FD9A9E4C6Q33851627-19D821E3-FB0F-42E0-B7A7-275AE67600B8Q33872810-68E39698-4428-4840-9ABF-650D8C90F5F8Q33906239-2CE4D10E-EA18-42EE-A920-A8B43CBD52F8Q33959260-4178C023-BEE0-4398-B4F2-5A4ABD02A8E6Q33987492-7090BD8B-9CEF-4C4C-8F3F-A673BE37051CQ34110204-31132BBB-9C35-4D6A-84A4-C446C6818312Q34289973-40BF5840-1136-4328-8853-C475F58ECB7DQ34306474-D0D3C1AA-E219-4D83-85A0-A00148A830EFQ34443184-8963EF27-F777-41FD-84E1-AD0E8E4AFC3FQ34459409-20628134-C18C-4BAF-8A34-6019D628175FQ34519205-58F34C9D-AAED-4BA2-B5E3-AE21C74D5966Q34647446-24E46115-5109-42C8-9CF9-6A454A34D85EQ35063764-ED294B65-4541-4868-A407-82823FE38ED8Q35090710-D39A78C6-D516-462A-9E29-B86D242A5A2CQ35105761-D5DFA252-532E-42F5-817E-37E08BFD6AB3Q35120765-5555E0B0-585A-4F4C-876D-25C70DAA60D4Q35204373-CA9F26EA-71BC-4945-B10F-C76836900825Q35208371-7429EF18-91BD-43F8-A8A9-411D9A9E81F7Q35612098-541B82B0-E793-42FE-81B8-0FAF5C6771C4Q35689311-64067E30-F758-4FD4-BC91-073EB8C66A9BQ35699612-05276DD5-278C-4D9D-8A03-6F3FF74A409DQ35794241-A03A45A7-784D-4C76-A5F5-BFEA5D8BCE47Q35794287-657FA199-004B-485F-9B03-667B121EC26AQ35842270-1DD84655-F2B5-4B85-B46F-653F50672871
P2860
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Human immunodeficiency virus t ...... efavirenz combination therapy
@ast
Human immunodeficiency virus t ...... efavirenz combination therapy
@en
type
label
Human immunodeficiency virus t ...... efavirenz combination therapy
@ast
Human immunodeficiency virus t ...... efavirenz combination therapy
@en
prefLabel
Human immunodeficiency virus t ...... efavirenz combination therapy
@ast
Human immunodeficiency virus t ...... efavirenz combination therapy
@en
P2093
P2860
P1476
Human immunodeficiency virus t ...... efavirenz combination therapy
@en
P2093
D R Spalding
H J George
J Bunville
K Abremski
K Krakowski
P2860
P304
P356
10.1128/AAC.44.9.2475-2484.2000
P407
P577
2000-09-01T00:00:00Z